GAITHERSBURG, Md., April 05, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, Neximmune’s Chief Executive Officer, will be participating and presenting a corporate update at the following conferences:

Jefferies Immuno-Oncology Cell Therapy Summit
Friday, April 5^th, 3:05PM ET
Boston, MA

Solebury Trout Private Company Showcase
Thursday, April 18^th, 10:50AM ET
Boston, MA

About NexImmune
NexImmune is a biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics. The Company’s proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to create highly targeted T cell-based immunotherapies. In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system. For more information visit: www.neximmune.com

Contact
Chad Rubin
Solebury Trout
+1 (646) 378-2947
crubin@soleburytrout.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.